Project Grant R21NS131834

Award Date 9/18/23
Completion Date 8/31/25
Dollars Obligated $411K
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program provides funding for a pooled in vivo screening study to identify genetic combination therapies that can enhance axonal regeneration after spinal cord injury (SCI). The $437,250 award to the University of California, San Diego (UCSD) will support a two-part research study....
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $151,559 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Rensselaer Polytechnic Institute (RPI) to develop innovative magnetically responsive drug delivery electrospun fibers to improve regeneration after spinal cord injury (SCI). The project aims to create a novel biomaterial system that can release precise dosages of the anti-inflammatory cytokine...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, will fund research to develop a deep single-cell RNA sequencing approach to understand the molecular mechanisms regulating axon regeneration after spinal cord injury. Totaling $1,006,322, the award will support experiments to refine and expand a regeneration classifier built...
This $424,875.00 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will fund a comprehensive study of gene transcription patterns in diverse classes of neurons that connect the brain to the spinal cord after spinal cord injury in a mouse model. The research team at Marquette University will use single-cell sequencing technologies to profile...
This Project Grant award, titled "Promoting Spinal Cord Repair Using a Polymer-Based Drug Delivery System", is funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The $184,837 award aims to develop a novel polymer-based drug delivery system for localized intraspinal administration of gabapentinoid drugs to promote axon regeneration and functional...
The federal Project Grant award R01NS134695, totaling $586,525.00, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The primary purpose of this grant is to develop a non-invasive infrared light therapy and medical device to treat spinal cord injury (SCI). The project aims to reduce reactive oxygen species production and re-establish...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $506,696.00 to the University of Washington to conduct research on the microvascular response to traumatic spinal cord injury, with a focus on understanding age-related and sex differences in order to improve functional...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $218,068 to The Children's Hospital of Philadelphia Research Institute to conduct research aimed at understanding the mechanisms of glial response and axon regeneration after spinal cord injuries. The 2-year award, from October 3, 2024 to December 31, 2026, will support...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, will fund research to evaluate regulated PTEN expression for promoting axon regeneration and functional recovery after spinal cord injury (SCI). The $391,250 award to the University of Louisville will support three specific aims: 1) Temporal evaluation of PTEN knockdown...
This $291,020 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to investigate the molecular mechanisms regulating the neuron-glia switch in neural progenitor cells during development and after spinal cord injury. The research project, led by the University of Colorado-Denver, aims to determine how the Wnt signaling pathway modulates...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports development of a novel screening technology to identify FDA-approved drugs that can promote functional recovery in spinal cord injury (SCI). The $411,136 award to the Texas A&M University System Health Science Center will fund a 3-step screening platform using adult cortical neural cells from sheep and mice of varying ages and sexes. This screening approach aims to uncover beneficial compounds that were previously dismissed by conventional screens which do not account for age and sex differences. The project will screen over 2,800 approved drugs, with the goal of identifying at least one novel drug that can enhance recovery in a preclinical mouse model of SCI. Future efforts will focus on elucidating the underlying mechanisms of action and gathering data to enable Investigational New Drug (IND) application for clinical testing.

Generated 7/16/24, 7:35 AM